0001062993-22-009836.txt : 20220405
0001062993-22-009836.hdr.sgml : 20220405
20220405195418
ACCESSION NUMBER: 0001062993-22-009836
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220401
FILED AS OF DATE: 20220405
DATE AS OF CHANGE: 20220405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adda Nathalie
CENTRAL INDEX KEY: 0001646976
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35839
FILM NUMBER: 22809039
MAIL ADDRESS:
STREET 1: C/O ENANTA PHARMACEUTICALS, INC.
STREET 2: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001177648
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617 607 0800
MAIL ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2022-04-01
0001177648
ENANTA PHARMACEUTICALS INC
ENTA
0001646976
Adda Nathalie
C/O ENANTA PHARMACEUTICALS, INC.
500 ARSENAL STREET
WATERTOWN
MA
02472
0
1
0
0
Sr. VP & Chief Medical Officer
Common Stock
2022-04-01
4
M
0
16000
31.42
A
50982
D
Common Stock
2022-04-01
4
M
0
31664
30.00
A
82646
D
Common Stock
2022-04-01
4
M
0
2895
48.52
A
85541
D
Common Stock
2022-04-01
4
S
0
8299
70.75
D
77242
D
Common Stock
2022-04-01
4
S
0
42260
71.32
D
34982
D
Common Stock
2022-04-04
4
M
0
6285
48.52
A
41267
D
Common Stock
2022-04-04
4
M
0
9625
43.57
A
50892
D
Common Stock
2022-04-04
4
M
0
16875
63.35
A
67767
D
Common Stock
2022-04-04
4
S
0
2500
70.56
D
65267
D
Common Stock
2022-04-04
4
S
0
18076
71.71
D
47191
D
Common Stock
2022-04-04
4
S
0
3200
72.65
D
43991
D
Common Stock
2022-04-04
4
S
0
9009
73.42
D
34982
D
Stock Option (Right to Buy)
31.42
2022-04-01
4
M
0
16000
0
D
2025-11-20
Common Stock
16000
0
D
Stock Option (Right to Buy)
30.00
2022-04-01
4
M
0
31664
0
D
2026-11-18
Common Stock
31664
0
D
Stock Option (Right to Buy)
48.52
2022-04-01
4
M
0
2895
0
D
2027-11-17
Common Stock
2895
6285
D
Stock Option (Right to Buy)
48.52
2022-04-04
4
M
0
6285
0
D
2027-11-17
Common Stock
6285
0
D
Stock Option (Right to Buy)
43.57
2022-04-04
4
M
0
9625
0
D
2030-11-20
Common Stock
9625
21175
D
Stock Option (Right to Buy)
63.35
2022-04-04
4
M
0
16875
0
D
2029-11-18
Common Stock
16875
13125
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive.
100% of the shares subject to the option are fully vested and exercisable.
The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020).
The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019).
The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7 above.
/s/ Nathaniel S. Gardiner as attorney-in-fact
2022-04-05